Contributions
Abstract: EP1428
Type: ePoster
Abstract Category: Clinical aspects of MS - 9 Economic burden
Background: Nowadays efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS) are well known but it lacks data to evaluate its cost-effectiveness. This knowledge would be useful to improve clinical management and to establish risk-sharing schemes of payment in health systems.
Objective: To analyze the cost per year of a relapse-free patient in a cohort of relapsing remitting multiple sclerosis (RRMS) treated with first or second-line DMTs.
Patients and methods: Patients diagnosed with MS, followed in our MS unit and belonging to our health district in 2016 were evaluated. Our health district comprised 201192 inhabitants by 2016 and our center has the only MS unit. From them, patients diagnosed with RRMS were retrospectively selected for this study. Clinical and radiological data was collected prospectively using the European Database for Multiple Sclerosis (EDMUS) on a 6-monthly basis and at the time of relapse. Patients were classified in two groups, treated and not treated with DMTs during 2016 and in another two groups according to the presence or absence of at least one relapse during the same year. The mean cost of DMTs during 2016 of all RRMS patients was analyzed as well as the cost of a relapse-free patient.
Results: 181 patients from our health district were diagnosed with MS and followed in our MS unit, resulting in an MS prevalence of 90 per 100000 inhabitants. This rate was representative of the expected prevalence of MS in epidemiological population-based studies performed in our area. 158 patients diagnosed with RRMS were selected for our study. They were 71% women, their mean age at onset was 30.6 years, their mean disease duration was 16.3 years, and their median irreversible EDSS was 2.0. From them, 101 patients (63.9% of the cohort, 95% CI: 56,2-71.0%) were treated with DMTs during 2016. 120 patients (75,9% of the cohort, 95% CI 68.7-81.9%) remained free of relapses during 2016. The mean cost of DMTs per patient in 2016 was 7414.3 euros (95% CI: 6325.2-8503.4) when we considered all RRMS patients. The cost per year of DMTs of a relapse-free patient was 9762.2 euros.
Conclusion: The cost per year of a relapse-free patient may be a good health indicator to evaluate cost-effectiveness in RRMS patients treated with DMTs and to compare one population to another.
Disclosure: L.Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
E.Matas received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Bau received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
V. Casado received research support from Novartis and funding for travel and congress expenses from Almirall and Merck Serono.
M. Huerta: nothing to disclose.
R. Juvany: nothing to disclose.
A. Martínez-Yélamos received received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
S. Martínez-Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
Abstract: EP1428
Type: ePoster
Abstract Category: Clinical aspects of MS - 9 Economic burden
Background: Nowadays efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS) are well known but it lacks data to evaluate its cost-effectiveness. This knowledge would be useful to improve clinical management and to establish risk-sharing schemes of payment in health systems.
Objective: To analyze the cost per year of a relapse-free patient in a cohort of relapsing remitting multiple sclerosis (RRMS) treated with first or second-line DMTs.
Patients and methods: Patients diagnosed with MS, followed in our MS unit and belonging to our health district in 2016 were evaluated. Our health district comprised 201192 inhabitants by 2016 and our center has the only MS unit. From them, patients diagnosed with RRMS were retrospectively selected for this study. Clinical and radiological data was collected prospectively using the European Database for Multiple Sclerosis (EDMUS) on a 6-monthly basis and at the time of relapse. Patients were classified in two groups, treated and not treated with DMTs during 2016 and in another two groups according to the presence or absence of at least one relapse during the same year. The mean cost of DMTs during 2016 of all RRMS patients was analyzed as well as the cost of a relapse-free patient.
Results: 181 patients from our health district were diagnosed with MS and followed in our MS unit, resulting in an MS prevalence of 90 per 100000 inhabitants. This rate was representative of the expected prevalence of MS in epidemiological population-based studies performed in our area. 158 patients diagnosed with RRMS were selected for our study. They were 71% women, their mean age at onset was 30.6 years, their mean disease duration was 16.3 years, and their median irreversible EDSS was 2.0. From them, 101 patients (63.9% of the cohort, 95% CI: 56,2-71.0%) were treated with DMTs during 2016. 120 patients (75,9% of the cohort, 95% CI 68.7-81.9%) remained free of relapses during 2016. The mean cost of DMTs per patient in 2016 was 7414.3 euros (95% CI: 6325.2-8503.4) when we considered all RRMS patients. The cost per year of DMTs of a relapse-free patient was 9762.2 euros.
Conclusion: The cost per year of a relapse-free patient may be a good health indicator to evaluate cost-effectiveness in RRMS patients treated with DMTs and to compare one population to another.
Disclosure: L.Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
E.Matas received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Bau received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
V. Casado received research support from Novartis and funding for travel and congress expenses from Almirall and Merck Serono.
M. Huerta: nothing to disclose.
R. Juvany: nothing to disclose.
A. Martínez-Yélamos received received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
S. Martínez-Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.